Arcus Biosciences Inc. (RCUS) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Arcus Biosciences Inc. (NYSE: RCUS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $17.85 (-1.87% 1D, market cap $2.32B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RCUS ranks #989 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCUS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBH (Prestige Consumer Healthcare Inc.) holds a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B) and BHVN (Biohaven Ltd.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $2.33B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).
Per RCUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001724521), Arcus Biosciences Inc. generated $33.0M in revenue (-35.3% YoY), -$353.0M in net income, and -$484.0M in free cash flow against $1.14B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While RCUS currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.50) and Max Pain ($18.74) forces dealer call-delta covering toward $33.33.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Arcus Biosciences Inc. (RCUS) slipped -1.87% to $17.85, trading at 3% of its 52-week range ($17.43 – $31.74). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
AlphaStreet report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares increased
HAYWARD, Calif., October 26, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of can
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -35.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RCUS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RCUS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Arcus Biosciences Inc. (RCUS) ranks #989 by composite RQD confidence (19/100, grade E) and #232 by equity capitalization ($2.32B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with RCUS at 19/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RCUS
ACTIVE
Arcus Biosciences Inc. | E | 19/100 | — | — | -35.0% | -1.87% | $2.32B | Benchmark Subject |
| PBH Prestige Consumer Healthcare Inc. | C | 62/100 | 12.1x | 54.7% | 13.8% | +1.37% | $2.32B | /pbh-vs-rcus → |
| BHVN Biohaven Ltd. | D | 44/100 | — | — | -35.0% | -1.69% | $2.33B | /bhvn-vs-rcus → |
| PHVS Pharvaris N.V. | C- | 59/100 | — | — | — | 0.00% | $2.34B | /phvs-vs-rcus → |
| HCM HUTCHMED (China) Limited | E | 34/100 | 5.2x | — | -2.5% | +0.91% | $2.29B | /hcm-vs-rcus → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arcus Biosciences Inc. (RCUS) reported GAAP revenue of $33.0M (-35.3% vs. FY2024 revenue of $51.0M , and -10.8% cumulative change since FY2023) , GAAP net income of -$353.0M, operating cash flow of -$482.0M, and free cash flow of -$484.0M (-175.0% YoY). On the balance sheet, RCUS closed FY2025 with $1.14B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $33.0M | -$353.0M | -$482.0M | -$484.0M | $1.14B | — |
| FY2024 (FY) | 2024-12-31 | $51.0M | -$283.0M | -$170.0M | -$176.0M | $1.15B | — |
| FY2023 (FY) | 2023-12-31 | $37.0M | -$307.0M | -$306.0M | -$306.0M | — | — |
As of 2026-11-03, Arcus Biosciences Inc. (NYSE: RCUS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $17.85 (-1.87% 1D, market cap $2.32B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RCUS ranks #989 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCUS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBH (Prestige Consumer Healthcare Inc.) holds a C grade (62/100 RQD, P/E 12.1x, ROIC 13.8%, cap $2.32B) and BHVN (Biohaven Ltd.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $2.33B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).
Per RCUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001724521), Arcus Biosciences Inc. generated $33.0M in revenue (-35.3% YoY), -$353.0M in net income, and -$484.0M in free cash flow against $1.14B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RCUS last traded at $17.85 (-1.87% on volume of 1,380,522 shares), positioning the stock -27.14% below its 50-day simple moving average ($24.50) and -27.53% below its 200-day simple moving average ($24.63). Across its 52-week range of $17.43 to $31.74, RCUS sits at the 2.9% percentile with a 14-day RSI of 31.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($15.62 to $20.08).
Arcus Biosciences Inc. (RCUS) earns a live Roarable RQD composite score of 19/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $17.85 (-1.87% 1D, market capitalization $2.32B).
Arcus Biosciences Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company's market capitalization is $2.4B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Arcus Biosciences Inc. (RCUS) reported $33.0M in annual revenue (up from $51.0M in FY2024, -35.3% YoY) and -$353.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($37.0M revenue, -$307.0M net income) through FY2025, RCUS scaled operating cash flow to -$482.0M and free cash flow to -$484.0M, backed by $1.14B in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), RCUS carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Arcus Biosciences Inc. (RCUS) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
AlphaStreet report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Investor's Business Daily report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Arcus Biosciences Inc. (RCUS) market action, institutional positioning, and fundamental catalysts.
Don't sleep on RCUS's setup in Health Care. Recent news flow cites a surge on kidney-cancer data and the price sits 6.7% above its 52-week low of $17.43.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (19/100) backs up the fundamental quality.
Both sides have a point here — RCUS's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Here is the bear case nobody on the bull side wants to address on RCUS: A -35% ROIC, -20.42% FCF yield, and a Piotroski F-Score of 1/9 point to sustained cash burn and weak fundamental quality.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).